1. Mgl2 + cDC2s coordinate fungal allergic airway type 2, but not type 17, inflammation in mice.
- Author
-
Cook PC, Brown SL, Houlder EL, Furlong-Silva J, Conn DP, Colombo SAP, Baker S, Svedberg FR, Howell G, Bertuzzi M, Boon L, Konkel JE, Thornton CR, Allen JE, and MacDonald AS
- Subjects
- Animals, Mice, Mice, Inbred C57BL, Lung immunology, Lung microbiology, Lung pathology, Asthma immunology, Asthma microbiology, Spores, Fungal immunology, Inflammation immunology, CD11c Antigen metabolism, Receptors, CCR7 metabolism, Receptors, CCR7 genetics, CD4-Positive T-Lymphocytes immunology, Female, Disease Models, Animal, Single-Cell Analysis, Mice, Knockout, Dendritic Cells immunology, Lectins, C-Type metabolism, Lectins, C-Type genetics
- Abstract
Fungal spores are abundant in the environment and a major cause of asthma. Originally characterised as a type 2 inflammatory disease, allergic airway inflammation that underpins asthma can also involve type 17 inflammation, which can exacerbate disease causing failure of treatments tailored to inhibit type 2 factors. However, the mechanisms that determine the host response to fungi, which can trigger both type 2 and type 17 inflammation in allergic airway disease, remain unclear. Here we find that CD11c
+ DCs and CD4+ T cells are essential for development of both type 2 and type 17 airway inflammation in mice repeatedly exposed to inhaled spores. Single cell RNA-sequencing with further multi-parameter cytometry shows that allergic inflammation dramatically alters the proportion of numerous DC clusters in the lung, but that only two of these (Mgl2+ cDC2s and CCR7+ DCs) migrate to the dLNs. Targeted removal of several DC subsets shows that Mgl2+ cDC2 depletion reduces type 2, but not type 17, fungal allergic airway inflammation. These data highlight distinct DC subsets as potential therapeutic targets for the treatment of pulmonary fungal disease., Competing Interests: Competing interests: Individuals based at the Lydia Becker Institute received funding from GSK. These authors (P.C.C., S.L.B, E.L.H., F.R.S., A.S.M.) declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The remaining authors declare no competing interests., (© 2025. The Author(s).)- Published
- 2025
- Full Text
- View/download PDF